- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- EDP-938, Placebo
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 28 Days to 36 Months
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 16
- States / cities
- Long Beach, California • Los Angeles, California • Sacramento, California + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1561–1569
of 1,569
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Kidney Transplantation, Delayed Graft Function
- Interventions
- CellCept
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Constipation, Bowel Dysfunction
- Interventions
- alvimopan, placebo
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 233 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 69
- States / cities
- Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 58 more
- Conditions
- Diabetic Macular Edema
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 48
- States / cities
- La Jolla, California • Redlands, California • Santa Maria, California + 44 more
- Conditions
- Graves Disease, Hashimoto Disease
- Interventions
- Dexamethasone, Placebo
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Indianapolis, Indiana
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- CK0803, Excipient
- Biological · Other
- Lead sponsor
- Cellenkos, Inc.
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Wilson Disease
- Interventions
- UX701, Standard of Care (SOC)
- Genetic · Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2034
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Redwood City, California • Sacramento, California + 9 more
- Conditions
- Postoperative Gastrointestinal Dysfunction
- Interventions
- TAK-954 Placebo, TAK-954
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 209 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 19
- States / cities
- Mobile, Alabama • Los Angeles, California • Orange, California + 14 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Ranolazine, Placebo, Diet, Exercise
- Drug · Behavioral
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 57
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 49 more